TW230206B - - Google Patents

Info

Publication number
TW230206B
TW230206B TW082100802A TW82100802A TW230206B TW 230206 B TW230206 B TW 230206B TW 082100802 A TW082100802 A TW 082100802A TW 82100802 A TW82100802 A TW 82100802A TW 230206 B TW230206 B TW 230206B
Authority
TW
Taiwan
Application number
TW082100802A
Other languages
Chinese (zh)
Inventor
E Mulle Ulrich
Muller-Gliemann Marrhias
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of TW230206B publication Critical patent/TW230206B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
TW082100802A 1992-02-27 1993-02-06 TW230206B (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4206045A DE4206045A1 (de) 1992-02-27 1992-02-27 Sulfonylbenzyl substituierte pyridone

Publications (1)

Publication Number Publication Date
TW230206B true TW230206B (cg-RX-API-DMAC7.html) 1994-09-11

Family

ID=6452730

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082100802A TW230206B (cg-RX-API-DMAC7.html) 1992-02-27 1993-02-06

Country Status (18)

Country Link
US (1) US5254543A (cg-RX-API-DMAC7.html)
EP (1) EP0557843A3 (cg-RX-API-DMAC7.html)
JP (1) JPH0641081A (cg-RX-API-DMAC7.html)
KR (1) KR930017898A (cg-RX-API-DMAC7.html)
CN (1) CN1078468A (cg-RX-API-DMAC7.html)
AU (1) AU653288B2 (cg-RX-API-DMAC7.html)
CA (1) CA2090267A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ15793A3 (cg-RX-API-DMAC7.html)
DE (1) DE4206045A1 (cg-RX-API-DMAC7.html)
HU (1) HUT64057A (cg-RX-API-DMAC7.html)
IL (1) IL104843A0 (cg-RX-API-DMAC7.html)
MX (1) MX9300766A (cg-RX-API-DMAC7.html)
MY (1) MY129973A (cg-RX-API-DMAC7.html)
NZ (1) NZ245999A (cg-RX-API-DMAC7.html)
PL (1) PL297870A1 (cg-RX-API-DMAC7.html)
SK (1) SK14593A3 (cg-RX-API-DMAC7.html)
TW (1) TW230206B (cg-RX-API-DMAC7.html)
ZA (1) ZA931370B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4215587A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
JPH06306073A (ja) * 1992-12-10 1994-11-01 Japan Tobacco Inc ニコチン誘導体の光学分割法
WO2000058304A1 (en) * 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
CA2469435A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AP1822A (en) * 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
BRPI0608469A2 (pt) 2005-04-22 2010-01-05 Alantos Pharmaceuticals Holding Inc inibidores de dipeptidil peptidase-iv
GB0514686D0 (en) * 2005-07-18 2005-08-24 Novartis Ag Organic compounds
CN1985878B (zh) * 2005-12-20 2011-06-22 广州王老吉药业股份有限公司 一种治疗消化性溃疡的药物组合物及其制备方法
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2009033703A1 (en) * 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
RS51660B (sr) 2007-09-14 2011-10-31 Ortho-Mcneil-Janssen Pharmaceuticals Inc. 1`,3`-disupstituisani-4-fenil-3,4,5,6-tetrahidro-2h, 1`h-[1,4`] bipiridinil-2`-oni
EP2220083B1 (en) * 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
AU2009331659B2 (en) 2008-12-23 2015-09-03 F. Hoffmann-La Roche Ag Dihydropyridone amides as P2X7 modulators
CN102264701A (zh) 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮脲
CA2745952A1 (en) 2008-12-23 2010-07-01 F.Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
WO2010072605A1 (en) 2008-12-23 2010-07-01 F. Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
US8153808B2 (en) 2008-12-23 2012-04-10 Roche Palo Alto Llc Dihydropyridone amides as P2X7 modulators
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
KR20120035158A (ko) 2009-05-12 2012-04-13 얀센 파마슈티칼즈, 인코포레이티드 1,2,4?트리아졸로[4,3?a]피리딘 유도체 및 mGluR2 수용체의 양성 알로스테릭 조절자로서의 그의 용도
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2814996C (en) 2010-11-08 2019-10-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
CN109999033B (zh) 2014-01-21 2022-12-23 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
HRP20191646T1 (hr) 2014-01-21 2019-12-13 Janssen Pharmaceutica Nv Kombinacije koje sadržavaju pozitivne alosteričke modulatore ili ortosteričke agoniste metabotropnog glutamatergičnog receptora podtip 2 i njihova uporaba

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406329A1 (de) * 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2018443A1 (en) * 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
SG52330A1 (en) * 1989-06-14 1998-09-28 Smithkline Beecham Corp Imidazolyl-alkenoic acids
FI916130A7 (fi) * 1989-06-30 1991-12-27 Du Pont Aryylisubstituoituja imidatsoleja
AU640417B2 (en) * 1989-10-25 1993-08-26 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles
NZ238624A (en) * 1990-06-19 1994-08-26 Meiji Seika Co Pyridine derivatives, compositions, preparations and use thereof

Also Published As

Publication number Publication date
IL104843A0 (en) 1993-06-10
HUT64057A (en) 1993-11-29
JPH0641081A (ja) 1994-02-15
CZ15793A3 (en) 1993-12-15
AU3377093A (en) 1993-09-02
CA2090267A1 (en) 1993-08-28
CN1078468A (zh) 1993-11-17
EP0557843A3 (en) 1993-12-01
AU653288B2 (en) 1994-09-22
ZA931370B (en) 1993-03-23
KR930017898A (ko) 1993-09-20
HU9300545D0 (en) 1993-05-28
MX9300766A (es) 1993-08-01
MY129973A (en) 2007-05-31
EP0557843A2 (de) 1993-09-01
NZ245999A (en) 1995-10-26
DE4206045A1 (de) 1993-09-02
US5254543A (en) 1993-10-19
PL297870A1 (en) 1993-10-04
SK14593A3 (en) 1993-10-06

Similar Documents

Publication Publication Date Title
TW218404B (cg-RX-API-DMAC7.html)
TW230206B (cg-RX-API-DMAC7.html)
DK0603481T3 (cg-RX-API-DMAC7.html)
DK0599160T3 (cg-RX-API-DMAC7.html)
DK0596750T3 (cg-RX-API-DMAC7.html)
DK0553681T3 (cg-RX-API-DMAC7.html)
DK0581129T3 (cg-RX-API-DMAC7.html)
DK0571172T3 (cg-RX-API-DMAC7.html)
DK0599441T3 (cg-RX-API-DMAC7.html)
TW249767B (cg-RX-API-DMAC7.html)
DK0559942T3 (cg-RX-API-DMAC7.html)
DK0590732T3 (cg-RX-API-DMAC7.html)
DE9209779U1 (cg-RX-API-DMAC7.html)
DE9207553U1 (cg-RX-API-DMAC7.html)
TW273569B (cg-RX-API-DMAC7.html)
IN180848B (cg-RX-API-DMAC7.html)
ECSDI920085S (cg-RX-API-DMAC7.html)
IN177394B (cg-RX-API-DMAC7.html)
IN181029B (cg-RX-API-DMAC7.html)
IN185126B (cg-RX-API-DMAC7.html)
AU1283492A (cg-RX-API-DMAC7.html)
EP0576831A3 (cg-RX-API-DMAC7.html)
EP0554883A3 (cg-RX-API-DMAC7.html)
AU1047592A (cg-RX-API-DMAC7.html)
AU1045392A (cg-RX-API-DMAC7.html)